Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Calithera Biosciences, Inc
Guizhou Medical University
SCRI Development Innovations, LLC
Spectrum Pharmaceuticals, Inc
University of Lausanne Hospitals
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Endocyte
Post Graduate Institute of Medical Education and Research, Chandigarh
Stanford University
Boehringer Ingelheim
Sun Yat-sen University
National Cancer Institute (NCI)
Wales Cancer Trials Unit
Eli Lilly and Company